APE1 and XRCC3 polymorphisms and myocardial infarction
Atike Tekeli1, Selim Isbir, Arzu Ergen
1Department of Molecular Medicine, The Institute of Experimental Medicine, Istanbul University, Capa-Istanbul, Turkey.
In Vivo (Athens, Greece)
|August 21, 2008
Summary
Genetic variations in the AP endonuclease 1 (APE1) and X-ray repair cross-complementing protein 3 (XRCC3) genes may increase myocardial infarction risk. Specifically, the APE1 AG genotype and XRCC3 TT genotype were more prevalent in patients with heart attacks.
Area of Science:
- Genetics
- Molecular Biology
- Cardiovascular Disease
Background:
- DNA damage from mutagens is common and can lead to diseases like cancer and aging if unrepaired.
- Specific DNA repair mechanisms target distinct types of DNA damage.
- Unrepaired free radical DNA damage is linked to gene expression decline and various pathologies.
Purpose of the Study:
- To investigate the association between APE1 and XRCC3 gene polymorphisms and myocardial infarction (MI).
Main Methods:
- Study included 45 patients undergoing coronary artery bypass grafting (CABG) and 40 healthy controls.
- Gene polymorphisms were analyzed using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique.
Main Results:
- The APE1 gene AG genotype was significantly more frequent in MI patients compared to controls.
- A higher prevalence of G carriers for the APE1 gene was observed in the patient group.
- The XRCC3 gene TT genotype was significantly more frequent in the MI patient group.
Conclusions:
- The XRCC3 TT genotype and APE1 AG genotype may be associated with an increased risk of myocardial infarction.
- These genetic polymorphisms could serve as potential biomarkers for cardiovascular disease risk assessment.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:20Imaging Studies for Cardiovascular System III: X-Ray
The most common cardiovascular diagnostic test is an X-ray. It produces images of the heart, blood vessels, and adjacent structures.
Definition and Purpose
An X-ray, or radiograph, is a non-invasive method that uses ionizing radiation to take images of internal structures. It is mainly used in cardiac imaging to examine the heart, lungs, and major blood vessels, aiming to identify abnormalities in the heart's size, shape, and position, such as heart failure, congenital defects, and vascular...
Definition and Purpose
An X-ray, or radiograph, is a non-invasive method that uses ionizing radiation to take images of internal structures. It is mainly used in cardiac imaging to examine the heart, lungs, and major blood vessels, aiming to identify abnormalities in the heart's size, shape, and position, such as heart failure, congenital defects, and vascular...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...